Doeleman MJH, de Roock S, El Amrani M, et al. - Researchers conducted the study for evaluating the association of adalimumab trough concentrations and treatment response in paediatric patients with juvenile idiopathic arthritis (JIA). It was a monocentric cohort study of JIA patients treated with adalimumab. During routine follow-up, clinical data and samples were obtained. Using the clinical Juvenile Arthritis Disease Activity Score with 71 joint-count (cJADAS71), disease activity was assessed. Thirty-five adalimumab trough samples were available from 34 paediatric patients with JIA. In JIA patients with secondary failure, adalimumab trough concentrations were substantially lower than in patients with primary failure or an appropriate response to adalimumab. Trough concentration measurements may be useful in identifying JIA patients who require higher adalimumab doses to achieve or maintain therapeutic drug concentrations.